Noxopharm Released December 2019 Quarterly Update Outlining Veyonda® Research Progress and Upcoming Activities.

  • Feb 03, 2020 AEDT
  • Team Kalkine


  • During the given period, Noxopharm’s (ASX:NOX) prime focus was on bringing Veyonda® towards achieving marketing approval, post observing impressive results in the DARRT-1 Phase 1b Study with 48% of men with Stage 4 prostate-cancer showing durable anti-cancer response at 6 months.
  • Given the encouraging positive outcomes of DARRT-1, the company is proceeding to multi-national placebo-controlled DARRT phase 2 clinical trial.
  • Noxopharm is expecting to release its well progressing LuPIN trial’s all-important overall survival data on the first 32 men by mid of February 2020.
  • Veyonda® is on its way to become groundbreaking immunotherapy for late-stage cancers.



All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK